Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.

Translational behavioral medicine - 29 Jan 2018

Aspinwall Lisa G, Stump Tammy K, Taber Jennifer M, Drummond Danielle M, Kohlmann Wendy, Champine Marjan, Leachman Sancy A

Abstract excerpt

A CDKN2A/p16 mutation confers 28%-67% lifetime melanoma risk, a risk that may be moderated by ultraviolet radiation exposure. The aim of this study was to test whether melanoma genetic counseling and test disclosure conferred unique informational, motivational, or emotional benefits compared to family history-based counseling. Participants included were 114 unaffected members of melanoma-prone families, ages...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase Inhibitor p16
Share to Cyclin-Dependent Kinase Inhibitor p18

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Counseling

Share to Health Behavior

Share to Health Knowledge, Attitudes, Practice

Share to Motivation

Share to Risk Reduction Behavior

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29385581
DOI: 10.1093/tbm/ibx011
PMCID: PMC6065541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.PMID 29385581Read ↗

Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.Semantic proximity Read ↗

Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress.Semantic proximity Read ↗

Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.Semantic proximity Read ↗

Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.Semantic proximity Read ↗

Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families.Semantic proximity Read ↗

Impact of melanoma genetic test reporting on perceived control over melanoma prevention.Semantic proximity Read ↗

Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers.Semantic proximity Read ↗

Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma.Semantic proximity Read ↗

Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic VariantsSemantic proximity Read ↗

Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall.Semantic proximity Read ↗

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.Semantic proximity Read ↗

Family risk discussions after feedback on genetic risk of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.